Bibliography for Cardiovascular Disease Management in Primary Care

[1]
R. Bonita, R. Beaglehole, T. Kjellström, World Health Organization, and Ebooks Corporation Limited, Basic epidemiology, 2nd edition. Geneva: World Health Organization, 2006 [Online]. Available: https://ebookcentral.proquest.com/lib/gla/detail.action?docID=284799

[2]
G. Rose, ‘Strategy of prevention : lessons from cardiovascular disease.’, BMJ, vol. 282, no. 6279, pp. 1847–1851, 1981, doi: 10.1136/bmj.282.6279.1847.

[3]
J. Hart, ‘Measurement of omission.’, BMJ, vol. 284, no. 6330, pp. 1686–1689, 1982, doi: 10.1136/bmj.284.6330.1686.

[4]
K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke, and B. Guthrie, ‘Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study’, The Lancet, vol. 380, no. 9836, pp. 37–43, Jul. 2012, doi: 10.1016/S0140-6736(12)60240-2.

[5]
M. Ezzati, Z. Obermeyer, I. Tzoulaki, B. M. Mayosi, P. Elliott, and D. A. Leon, ‘Contributions of risk factors and medical care to cardiovascular mortality trends’, Nature Reviews Cardiology, vol. 12, no. 9, pp. 508–530, Jun. 2015, doi: 10.1038/nrcardio.2015.82.

[6]
H. Richards, M. Reid, and G. Watt, ‘Socio-economic variations in responses to chest pain : a qualitative study’, BMJ, vol. 324, no. 7349, pp. 1308–1310, 2002, doi: 10.1136/bmj.324.7349.1308.

[7]
R. Jackson, S. Wells, and A. Rodgers, ‘Will screening individuals at high risk of cardiovascular events deliver large benefits? Yes’, BMJ, vol. 337, no. aug28 2, pp. a1371–a1371, Aug. 2008, doi: 10.1136/bmj.a1371.

[8]
S. Capewell, ‘Will screening individuals at high risk of cardiovascular events deliver large benefits? No’, BMJ, vol. 337, no. aug28 2, pp. a1395–a1395, Aug. 2008, doi: 10.1136/bmj.a1395.

[9]
S. Capewell and H. Graham, ‘Will Cardiovascular Disease Prevention Widen Health Inequalities?’, PLoS Medicine, vol. 7, no. 8, Aug. 2010, doi: 10.1371/journal.pmed.1000320.

[10]
J. P. D. Reckless, ‘Primary prevention of cardiovascular disease’, BMJ, vol. 342, no. jan25 4, pp. d201–d201, Jan. 2011, doi: 10.1136/bmj.d201.

[11]
A. D. Hingorani and H. Hemingway, ‘How should we balance individual and population benefits of statins for preventing cardiovascular disease?’, BMJ, vol. 342, no. jan26 1, pp. c6244–c6244, Jan. 2010, doi: 10.1136/bmj.c6244.

[12]
K. Khunti, N. Walker, N. Sattar, and M. Davies, ‘Unanswered questions over NHS health checks’, BMJ, vol. 342, no. jan26 1, pp. c6312–c6312, Feb. 2010, doi: 10.1136/bmj.c6312.

[13]
C. A. O’Donnell et al., ‘Delivering a national programme of anticipatory care in primary care: a qualitative study’, British Journal of General Practice, vol. 62, no. 597, pp. 288–296, Apr. 2012, doi: 10.3399/bjgp12X636137.

[14]
M. Linardakis, E. Smpokos, A. Papadaki, I. Komininos, N. Tzanakis, and A. Philalithis, ‘Prevalence of multiple behavioral risk factor for chronic diseases in adults aged 50+, from eleven European countries – the SHARE study (2004).’, vol. 57 (3), pp. 168–172 [Online]. Available: https://ezproxy.lib.gla.ac.uk/login?url=https://www.sciencedirect.com/science/article/pii/S0091743513001539

[15]
A. V. Prochazka and T. Caverly, ‘General Health Checks in Adults for Reducing Morbidity and Mortality From Disease’, JAMA Internal Medicine, vol. 173, no. 5, Mar. 2013, doi: 10.1001/jamainternmed.2013.3187.

[16]
M. Artac, A. Dalton, A. Majeed, J. Car, and C. Millett, ‘Effectiveness of a national cardiovascular disease risk assessment program (NHS Health Check): Results after one year.’, vol. 57 (2), pp. 129–134, 2013 [Online]. Available: https://ezproxy.lib.gla.ac.uk/login?url=https://www.sciencedirect.com/science/article/pii/S0091743513001473

[17]
‘World Health Organization pages on Cardiovascular Disease’. [Online]. Available: http://www.who.int/cardiovascular_diseases/en/

[18]
‘WHO Factsheet No 317 on Cardiovascular Diseases (CVDs) – updated January 2015.’ [Online]. Available: http://www.who.int/mediacentre/factsheets/fs317/en/

[19]
‘WHO Global Atlas on CVD Prevention and Control’. [Online]. Available: http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/

[20]
‘WHO Global Status Report on Noncommunicable Diseases 2014’. [Online]. Available: http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1

[21]
J. Cleland, H. Dargie, S. Hardman, T. McDonagh, and P. Mitchell, ‘National heart failure audit. April 2012-March 2013’. National Institute for Cardiovascular Outcomes Research (NICOR), 2013 [Online]. Available: http://www.wales.nhs.uk/sitesplus/documents/862/National%20Heart%20Failure%20Audit%20April%202012-March2013.pdf#:~:text=6%20National%20Heart%20Failure%20Audit%20April%202012-March%202013,the%202011%2F12%20cohort.%20This%20improvement%20reflects%20better%20treatment

[22]
‘Acute heart failure: diagnosis and management (NICE guidelines [CG187])’ [Online]. Available: https://www.nice.org.uk/guidance/cg187

[23]
‘Chronic heart failure in adults: management (NICE guidelines [CG108])’. National Institute for Health and Clinical Excellence [Online]. Available: http://www.nice.org.uk/guidance/cg108

[24]
P. Ponikowski et al., ‘2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure’, European Heart Journal, vol. 37, no. 27, pp. 2129–2200, Jul. 2016, doi: 10.1093/eurheartj/ehw128.

[25]
F. A. McAlister, S. Stewart, S. Ferrua, and J. J. J. V. McMurray, ‘Multidisciplinary strategies for the management of heart failure patients at high risk for admission’, Journal of the American College of Cardiology, vol. 44, no. 4, pp. 810–819, Aug. 2004, doi: 10.1016/j.jacc.2004.05.055.

[26]
J. Sochalski et al., ‘What Works In Chronic Care Management: The Case Of Heart Failure’, Health Affairs, vol. 28, no. 1, pp. 179–189, Jan. 2009, doi: 10.1377/hlthaff.28.1.179.

[27]
J. J. V. McMurray et al., ‘Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure’, New England Journal of Medicine, vol. 371, no. 11, pp. 993–1004, Sep. 2014, doi: 10.1056/NEJMoa1409077.

[28]
C. W. Yancy et al., ‘2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America’, Circulation, vol. 136, no. 6, pp. e137–e161, Aug. 2017, doi: 10.1161/CIR.0000000000000509.

[29]
J. Cleland, ‘The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis’, European Heart Journal, vol. 24, no. 5, pp. 442–463, Mar. 2003, doi: 10.1016/S0195-668X(02)00823-0.

[30]
‘SIGN 147: Management of chronic heart failure. A national clinical guideline.’ Scottish Intercollegiate Guidelines Network, Healthcare Improvement Scotland, 2016 [Online]. Available: http://www.sign.ac.uk/assets/sign147.pdf

[31]
J. A. Ezekowitz et al., ‘2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure’, Canadian Journal of Cardiology, vol. 33, no. 11, pp. 1342–1433, Nov. 2017, doi: 10.1016/j.cjca.2017.08.022.

[32]
B. Baron-Franco, G. McLean, F. S. Mair, V. L. Roger, B. Guthrie, and S. W. Mercer, ‘Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care’, British Journal of General Practice, vol. 67, no. 658, pp. e314–e320, May 2017, doi: 10.3399/bjgp17X690533.

[33]
‘Royal College of Physicians of Edinburgh Consensus Statement on Atrial Fibrillation’. 2012 [Online]. Available: https://www.rcpe.ac.uk/sites/default/files/files/final_statement.pdf

[34]
‘National clinical guidelines centre. Atrial fibrillation: The management of atrial fibrillation’. NICE, 2014 [Online]. Available: https://www.nice.org.uk/guidance/cg180

[35]
European society of cardiology, ‘Atrial Fibrillation 2016 (Management of) ESC Clinical Practice Guidelines’, 2016. [Online]. Available: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management

[36]
H. Heidbuchel et al., ‘Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation’, Europace, vol. 17, no. 10, pp. 1467–1507, Oct. 2015, doi: 10.1093/europace/euv309.

[37]
B. D. Jani et al., ‘Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort’, EP Europace, Nov. 2017, doi: 10.1093/europace/eux322.

[38]
A. Moya et al., ‘Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC)’, European Heart Journal, vol. 30, no. 21, pp. 2631–2671, Nov. 2009, doi: 10.1093/eurheartj/ehp298.

[39]
National Institute for Health and Care Excellence (NICE), ‘Transient loss of consciousness ('blackouts’) management in adults and young people’. [Online]. Available: https://www.nice.org.uk/guidance/cg109

[40]
M. Brignole et al., ‘Guidelines on management (diagnosis and treatment) of syncope – Update 2004’, European Heart Journal, vol. 25, no. 22, pp. 2054–2072, Nov. 2004, doi: 10.1016/j.ehj.2004.09.004.

[41]
H. Kabat and J. P. Anderson, ‘Acute Arrest of Cerebral Circulation in Man’, Archives of Neurology & Psychiatry, vol. 50, no. 5, pp. 510–528, Nov. 1943, doi: 10.1001/archneurpsyc.1943.02290230022002.

[42]
‘Determining driver fitness in Canada’. Canadian council of motor transport administrators [Online]. Available: https://www.transportation.alberta.ca/content/docType45/Production/CCMTADriverMedicalStandardsAugust2013.pdf

[43]
Scottish Intercollegiate Guidelines Network (SIGN), ‘Cardiac arrhythmias in coronary heart disease’. SIGN, Edinburgh, 2018 [Online]. Available: https://www.sign.ac.uk/assets/sign152.pdf

[44]
‘CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial’, The Lancet, vol. 385, no. 9985, pp. 2383–2391, Jun. 2015, doi: 10.1016/S0140-6736(15)60291-4.

[45]
P. S. Douglas et al., ‘Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease’, New England Journal of Medicine, vol. 372, no. 14, pp. 1291–1300, Apr. 2015, doi: 10.1056/NEJMoa1415516.

[46]
European Society of Cardiology, ‘Stable Coronary Artery Disease (Management of) ESC Clinical Practice Guidelines’, European Heart Journal, 2013. [Online]. Available: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Stable-Coronary-Artery-Disease-Management-of

[47]
‘SIGN 96 Scottish Intercollegiate Guidelines Network. management of stable angina’. [Online]. Available: http://www.sign.ac.uk/pdf/sign96.pdf

[48]
‘Angina - NICE CKS’. [Online]. Available: https://cks.nice.org.uk/angina

[49]
Scottish Intercollegiate Guidelines Network (SIGN), ‘Management of stable angina’. SIGN, Edinburgh, 2018 [Online]. Available: https://www.sign.ac.uk/sign-151-stable-angina

[50]
Y. Gan et al., ‘Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies’, BMC Psychiatry, vol. 14, no. 1, 2014, doi: 10.1186/s12888-014-0371-z.

[51]
B. D. Thombs et al., ‘Prevalence of depression in survivors of acute myocardial infarction’, Journal of General Internal Medicine, vol. 21, no. 1, pp. 30–38, Jan. 2006, doi: 10.1111/j.1525-1497.2005.00269.x.

[52]
J. H. Lichtman et al., ‘Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations: A Scientific Statement From the American Heart Association’, Circulation, vol. 129, no. 12, pp. 1350–1369, Mar. 2014, doi: 10.1161/CIR.0000000000000019.

[53]
A. Meijer, H. J. Conradi, E. H. Bos, B. D. Thombs, J. P. van Melle, and P. de Jonge, ‘Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research’, General Hospital Psychiatry, vol. 33, no. 3, pp. 203–216, May 2011, doi: 10.1016/j.genhosppsych.2011.02.007.

[54]
D. L. Hare, S. R. Toukhsati, P. Johansson, and T. Jaarsma, ‘Depression and cardiovascular disease: a clinical review’, European Heart Journal, vol. 35, no. 21, pp. 1365–1372, Jun. 2014, doi: 10.1093/eurheartj/eht462.

[55]
A. Meijer, M. Zuidersma, and P. de Jonge, ‘Depression as a non-causal variable risk marker in coronary heart disease’, BMC Medicine, vol. 11, no. 1, 2013, doi: 10.1186/1741-7015-11-130.

[56]
B. D. Thombs et al., ‘Does Evidence Support the American Heart Association’s Recommendation to Screen Patients for Depression in Cardiovascular Care? An Updated Systematic Review’, PLoS ONE, vol. 8, no. 1, Jan. 2013, doi: 10.1371/journal.pone.0052654.

[57]
M. A. Whooley et al., ‘Depressive Symptoms, Health Behaviors, and Risk of Cardiovascular Events in Patients With Coronary Heart Disease’, JAMA, vol. 300, no. 20, Nov. 2008, doi: 10.1001/jama.2008.711.

[58]
L. Poole, C. Dickens, and A. Steptoe, ‘The puzzle of depression and acute coronary syndrome: Reviewing the role of acute inflammation’, Journal of Psychosomatic Research, vol. 71, no. 2, pp. 61–68, Aug. 2011, doi: 10.1016/j.jpsychores.2010.12.009.

[59]
P. Harris, C. Sommargren, P. Stein, G. Fung, and B. Drew, ‘Heart rate variability measurement and clinical depression in acute coronary syndrome patients: narrative review of recent literature’, Neuropsychiatric Disease and Treatment, Jul. 2014, doi: 10.2147/NDT.S57523.

[60]
von K. R, ‘Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment: how strong is the evidence?’, Acta Psychiatr Scand, vol. 110, Sep. 2004, doi: 10.1111/j.1600-0447.2004.00308.x.

[61]
J. Jokinen and P. Nordström, ‘HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients’, Journal of Affective Disorders, vol. 116, no. 1–2, pp. 88–92, Jul. 2009, doi: 10.1016/j.jad.2008.10.025.

[62]
H. Baumeister, N. Hutter, and J. Bengel, ‘Psychological and pharmacological interventions for depression in patients with coronary artery disease’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: https://ezproxy.lib.gla.ac.uk/login?url=https://doi.wiley.com/10.1002/14651858.CD008012.pub3

[63]
P. J. Tully and H. Baumeister, ‘Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials’, BMJ Open, vol. 5, no. 12, Dec. 2015, doi: 10.1136/bmjopen-2015-009128.

[64]
J. J. V. McMurray et al., ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC’, European Heart Journal, vol. 33, no. 14, pp. 1787–1847, Jul. 2012, doi: 10.1093/eurheartj/ehs104.

[65]
T. Jaarsma et al., ‘Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology’, European Journal of Heart Failure, vol. 11, no. 5, pp. 433–443, May 2009, doi: 10.1093/eurjhf/hfp041.

[66]
‘End of life care in heart failure. A framework for implementation’. NHW Improving Quality, 2014 [Online]. Available: http://www.nhsiq.nhs.uk/media/2574509/end-of-life-care-in-heart-failure-framework-for-implementation.pdf

[67]
‘Living and dying well: a national action plan for palliative care and end of life care in Scotland’. The Scottish Government, 2008 [Online]. Available: http://www.palliativecarescotland.org.uk/content/publications/living-and-dying-well.pdf

[68]
‘Living and dying with advanced heart failure: a palliative care approach’. The Scottish Government, 2008 [Online]. Available: http://www.palliativecarescotland.org.uk/content/publications/HF-final-document.pdf

[69]
K. J. Hogg and S. M. M. Jenkins, ‘Prognostication or identification of palliative needs in advanced heart failure: where should the focus lie?’, Heart, vol. 98, no. 7, pp. 523–524, Apr. 2012, doi: 10.1136/heartjnl-2012-301753.

[70]
M. Johnson, J. Beattie, K. Hogg, and M. S. Watson, Heart failure: from advanced disease to bereavement, vol. Oxford specialist handbooks in end of life care. Oxford: Oxford University Press, 2012.

[71]
S. Browne, S. Macdonald, C. R. May, U. Macleod, and F. S. Mair, ‘Patient, Carer and Professional Perspectives on Barriers and Facilitators to Quality Care in Advanced Heart Failure’, PLoS ONE, vol. 9, no. 3, Mar. 2014, doi: 10.1371/journal.pone.0093288.

[72]
S. J. Pettit et al., ‘ICDs in end-stage heart failure’, BMJ Supportive & Palliative Care, vol. 2, no. 2, pp. 94–97, Jun. 2012, doi: 10.1136/bmjspcare-2011-000176.

[73]
J. C. Fang et al., ‘Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee’, Journal of Cardiac Failure, vol. 21, no. 6, pp. 519–534, Jun. 2015, doi: 10.1016/j.cardfail.2015.04.013.

[74]
M. R. Cowie et al., ‘e-Health: a position statement of the European Society of Cardiology’, European Heart Journal, vol. 37, no. 1, pp. 63–66, Jan. 2016, doi: 10.1093/eurheartj/ehv416.

[75]
R. J. Widmer, N. M. Collins, C. S. Collins, C. P. West, L. O. Lerman, and A. Lerman, ‘Digital Health Interventions for the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis’, Mayo Clinic Proceedings, vol. 90, no. 4, pp. 469–480, Apr. 2015 [Online]. Available: https://ezproxy.lib.gla.ac.uk/login?url=https://link.galegroup.com/apps/doc/A411614975/AONE?u=glasuni&sid=AONE&xid=0e272c31

[76]
S. C. Inglis et al., ‘Structured telephone support or telemonitoring programmes for patients with chronic heart failure’, Cochrane Database of Systematic Reviews, Sep. 1996, doi: 10.1002/14651858.CD007228.pub2. [Online]. Available: https://ezproxy.lib.gla.ac.uk/login/?url=https://doi.wiley.com/10.1002/14651858.CD007228.pub2

[77]
I. Frederix et al., ‘Medium-Term Effectiveness of a Comprehensive Internet-Based and Patient-Specific Telerehabilitation Program With Text Messaging Support for Cardiac Patients: Randomized Controlled Trial’, Journal of Medical Internet Research, vol. 17, no. 7, Jul. 2015, doi: 10.2196/jmir.4799.

[78]
‘E-Health Strategy 2011-2017’. The Scottish Government and NHS Scotland [Online]. Available: http://www.scotland.gov.uk/Publications/2011/09/09103110/0

[79]
E. Murray et al., ‘Why is it difficult to implement e-health initiatives? A qualitative study’, Implementation Science, vol. 6, no. 1, 2011, doi: 10.1186/1748-5908-6-6.

[80]
F. S. Mair, C. May, C. O’Donnell, T. Finch, F. Sullivan, and E. Murray, ‘Factors that promote or inhibit the implementation of e-health systems: an explanatory systematic review’, Bulletin of the World Health Organization, vol. 90, no. 5, pp. 357–364, May 2012, doi: 10.2471/BLT.11.099424.

[81]
L. E. Burke et al., ‘Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention’, Circulation, vol. 132, no. 12, pp. 1157–1213, Sep. 2015, doi: 10.1161/CIR.0000000000000232.

[82]
S. O’Connor, P. Hanlon, C. A. O’Donnell, S. Garcia, J. Glanville, and F. S. Mair, ‘Understanding factors affecting patient and public engagement and recruitment to digital health interventions: a systematic review of qualitative studies’, BMC Medical Informatics and Decision Making, vol. 16, no. 1, Dec. 2016, doi: 10.1186/s12911-016-0359-3.

[83]
M. R. Lennon et al., ‘Readiness for Delivering Digital Health at Scale: Lessons From a Longitudinal Qualitative Evaluation of a National Digital Health Innovation Program in the United Kingdom’, Journal of Medical Internet Research, vol. 19, no. 2, Feb. 2017, doi: 10.2196/jmir.6900.

[84]
F. S. Mair and C. R. May, ‘Thinking about the burden of treatment’, BMJ, vol. 349, no. nov10 4, pp. g6680–g6680, Nov. 2014, doi: 10.1136/bmj.g6680.

[85]
C. May, V. M. Montori, and F. S. Mair, ‘We need minimally disruptive medicine’, BMJ, vol. 339, no. aug11 2, pp. b2803–b2803, Aug. 2009, doi: 10.1136/bmj.b2803.

[86]
A. M. Abu Dabrh, K. Gallacher, K. R. Boehmer, H. I.G., and M. F.S., ‘Minimally disruptive medicine: the evidence and conceptual progress supporting a new era of healthcare’, Journal of the Royal College of Physicians of Edinburgh, vol. 45, no. 2, pp. 114–117, 2015 [Online]. Available: http://www.rcpe.ac.uk/sites/default/files/mair.pdf

[87]
N. D. Shippee, S. V. Allen, A. L. Leppin, C. R. May, and V. M. Montori, ‘Attaining minimally disruptive medicine: context, challenges and a roadmap for implementation’, Journal of the Royal College of Physicians of Edinburgh, vol. 45, no. 2, pp. 118–122, 2015 [Online]. Available: https://www.rcpe.ac.uk/sites/default/files/shippee.pdf

[88]
K. Gallacher, C. R. May, V. M. Montori, and F. S. Mair, ‘Understanding Patients’ Experiences of Treatment Burden in Chronic Heart Failure Using Normalization Process Theory’, The Annals of Family Medicine, vol. 9, no. 3, pp. 235–243, May 2011, doi: 10.1370/afm.1249.

[89]
N. D. Shippee, N. D. Shah, C. R. May, F. S. Mair, and V. M. Montori, ‘Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice’, Journal of Clinical Epidemiology, vol. 65, no. 10, pp. 1041–1051, Oct. 2012, doi: 10.1016/j.jclinepi.2012.05.005.

[90]
C. R. May et al., ‘Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness’, BMC Health Services Research, vol. 14, no. 1, 2014, doi: 10.1186/1472-6963-14-281.

[91]
B. Jani et al., ‘Identifying treatment burden as an important concept for end of life care in those with advanced heart failure’, Current Opinion in Supportive and Palliative Care, vol. 7, no. 1, pp. 3–7, Mar. 2013, doi: 10.1097/SPC.0b013e32835c071f.

[92]
K. Gallacher et al., ‘Uncovering Treatment Burden as a Key Concept for Stroke Care: A Systematic Review of Qualitative Research’, PLoS Medicine, vol. 10, no. 6, Jun. 2013, doi: 10.1371/journal.pmed.1001473.

Bibliography for Cardiovascular Disease Management in Primary Care BETA